Literature DB >> 23913314

A case of Fabry nephropathy with histological features of oligonephropathy.

Masashi Nishida1, Kitaro Kosaka, Koh Hasegawa, Kousuke Nishikawa, Toshiyuki Itoi, Takahiro Tsukimura, Tadayasu Togawa, Hitoshi Sakuraba, Kenji Hamaoka.   

Abstract

UNLABELLED: Newborn screening studies indicate the expected high incidence of later-onset Fabry disease with silent Fabry nephropathy while, with recent improved clinical care of premature infants, children with congenital oligonephropathy caused by premature embryonal development of the kidney are thought to be increasing. However, the coexistence of Fabry nephropathy and oligonephropathy has not been reported previously. We present the case of a 13-year-old boy who was diagnosed with Fabry nephropathy accompanied with histological features of oligonephropathy. He was born as a preterm baby, and a renal biopsy was performed because of mild renal dysfunction and mild proteinuria. He had neither characteristic early symptoms nor a family history of Fabry disease. Histologic findings demonstrated diffuse global enlargement and foamy change of podocytes with markedly decreased number and enlargement of the glomeruli. Both his plasma and leukocyte α-galactosidase A (GLA) activities were markedly decreased, and the plasma globotriaosylsphingosine and urine globotriaosylceramide levels were increased. Gene analysis revealed a missense mutation, R112H, in the GLA gene, which had been reported in the later-onset phenotype of Fabry patients. He is now under treatment with enzyme replacement therapy and an angiotensin-converting enzyme inhibitor.
CONCLUSION: This case indicated the possible co-occurrence of Fabry nephropathy and oligonephropathy. For early diagnosis and timely management, careful examinations for proteinuria and renal function, in addition to establishing an effective screening system for Fabry disease, will be necessary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913314     DOI: 10.1007/s00431-013-2118-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

Review 1.  The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity.

Authors:  Stacy Beck; Daniel Wojdyla; Lale Say; Ana Pilar Betran; Mario Merialdi; Jennifer Harris Requejo; Craig Rubens; Ramkumar Menon; Paul F A Van Look
Journal:  Bull World Health Organ       Date:  2009-09-25       Impact factor: 9.408

2.  Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Authors:  Christoph Wanner; João P Oliveira; Alberto Ortiz; Michael Mauer; Dominique P Germain; Gabor E Linthorst; Andreas L Serra; László Maródi; Renzo Mignani; Bruno Cianciaruso; Bojan Vujkovac; Roberta Lemay; Dana Beitner-Johnson; Stephen Waldek; David G Warnock
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 8.237

Review 3.  Oligonephropathy of prematurity.

Authors:  Yogavijayan Kandasamy; Roger Smith; Ian M R Wright
Journal:  Am J Perinatol       Date:  2011-11-17       Impact factor: 1.862

4.  [Long term renal outcome of children born preterm: a regular follow-up is needed].

Authors:  J Bacchetta; J Harambat; B Guy; G Putet; P Cochat; L Dubourg
Journal:  Arch Pediatr       Date:  2009-09       Impact factor: 1.180

5.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

6.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

7.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert Dobrovolny; Ai-Chu Huang; Hui-Ying Yeh; May-Chin Chao; Shio-Jean Lin; Teruo Kitagawa; Robert J Desnick; Li-Wen Hsu
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

8.  Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.

Authors:  Takahito Inoue; Kiyoko Hattori; Kenji Ihara; Atsushi Ishii; Kimitoshi Nakamura; Shinichi Hirose
Journal:  J Hum Genet       Date:  2013-05-16       Impact factor: 3.172

Review 9.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

10.  Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis.

Authors:  Jeffrey B Hodgin; Majid Rasoulpour; Glen S Markowitz; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 8.237

View more
  2 in total

1.  The 30-year Natural History of Non-classic Fabry Disease with an R112H Mutation.

Authors:  Reiko Muto; Koji Inagaki; Noritoshi Kato; Shoichi Maruyama; Toshiyuki Akahori
Journal:  Intern Med       Date:  2021-11-20       Impact factor: 1.282

Review 2.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.